impact of the economic crisis on the global pharmaceutical sector l.
Download
Skip this Video
Download Presentation
Impact of the Economic Crisis on the Global Pharmaceutical Sector

Loading in 2 Seconds...

play fullscreen
1 / 23

Impact of the Economic Crisis on the Global Pharmaceutical Sector - PowerPoint PPT Presentation


  • 124 Views
  • Uploaded on

Impact of the Economic Crisis on the Global Pharmaceutical Sector . Richard Laing MIE/EMP & Iris Buysse (University of Utrecht) with materials provided by Peter Stephens from IMS Health Utrecht 7 th January 2010. In the 97-99 Asian crisis consumption declines lagged GDP decline. . ,.

loader
I am the owner, or an agent authorized to act on behalf of the owner, of the copyrighted work described.
capcha
Download Presentation

PowerPoint Slideshow about 'Impact of the Economic Crisis on the Global Pharmaceutical Sector' - hien


Download Now An Image/Link below is provided (as is) to download presentation

Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.


- - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - -
Presentation Transcript
impact of the economic crisis on the global pharmaceutical sector

Impact of the Economic Crisis on the Global Pharmaceutical Sector

Richard Laing MIE/EMP &

Iris Buysse (University of Utrecht)

with materials provided by Peter Stephens from IMS Health

Utrecht

7th January 2010

in the 97 99 asian crisis consumption declines lagged gdp decline
In the 97-99 Asian crisis consumption declines lagged GDP decline.

,

Real GDP (LCU) (Q2 ’97=1)

Drug Consumption (SU) (Q2 ’97=1)

1.4

1.4

1.3

1.3

Korea

1.2

1.2

1.1

1.1

Thailand

Thailand

Indonesia

Indonesia

1.0

1.0

0.9

Korea

0.9

0.8

0.0

0.0

# of Quarters

Q0 = Q2 ’97

# of Quarters

Q0 = Q2 ’97

Source: ????

Source: IMS Midas

chronic disease consumption recovered quicker than overall consumption

,

Chronic disease consumption recovered quicker than overall consumption.

Real GDP (LCU) (Q2 ’97=1)

Chronic Disease Consumption (SU) (Q2 ’97=1)

1.4

1.4

1.3

1.3

Korea

1.2

1.2

Thailand

1.1

Korea

1.1

Thailand

Indonesia

Indonesia

1.0

1.0

0.9

0.9

0.8

0.0

0.0

# of Quarters

Q0 = Q2 ’97

# of Quarters

Q0 = Q2 ’97

Source: WHO

Source: IMS Midas

acute disease drug consumption recovers more slowly than gdp

,

Acute disease drug consumption recovers more slowly than GDP.

Real GDP (LCU) (Q2 ’97=1)

Acute Disease Consumption (SU) (Q2 ’97=1)

1.4

1.4

1.3

1.3

1.2

Korea

1.2

1.1

Indonesia

1.1

Thailand

1.0

Indonesia

Thailand

0.9

1.0

0.8

0.9

0.7

Korea

0.0

0.0

# of Quarters

Q0 = Q2 ’97

# of Quarters

Q0 = Q2 ’97

Source: WHO

Source: IMS Midas

slide5
The WHO, in collaboration with IMS, has established a programme to monitor the impact of the 08/09/?? recession

83 countries, approximately 81% of global population, quarterly reports (Small, poor and African countries missing)

Impact on consumption (Lagging indicator)

Total volume

Volume of acute and chronic medicines

Movement to or from original and licensed branded medicines

Impact on expenditure (Leading indicators)

Total expenditure

Average price per unit of volume (SU)

ims data sources and analysis methods
IMS Data Sources and Analysis Methods

IMS collects data on consumption and prices at one point in the distribution channel.

Data generally collected from private sector but in many countries the private sector supplies the public sector. Generally do not capture tender data

In some countries only captures hospital data (e.g. China)

Uses the same point and methods in each country, so good for detecting changes less so for cross country comparisons

Volume data is more reliable than pricing data

next steps
Next steps
  • Pareto analysis on ATC2 and ATC3-level on consumption distribution for 6 most affected countries
  • ATC-2 & 3 level analysis to identify top and bottom 10 of most decline
  • Investigate whether Individual product level data can identify marker medicines within ATC4 categories
slide19
Q4 07-Q1 08 compared to Q4 08-Q1 09ATC2: Top 10 decliners of the 30% of categories that account for 80% of consumption
slide20

Q4 07-Q1 08 compared to Q4 08-Q1 09ATC2: Bottom 10 decliners of the 30% of categories that account for 80% of consumption

work underway to be presented on january 8 th by iris buysse
Work underway to be presented on January 8th by Iris Buysse
  • ATC2 analysis
  • Identification of marker product categories for detecting declines that are likely to be therapeutically significant
  • More work to be done on ATC3 and ATC 4 data
further work to be undertaken in 2010
Further work to be undertaken in 2010
  • Meet to discuss further work to be done in Baltic states to link IMS consumption data with social security utilization & claims data. Possibly involve Iceland
  • Interim report for WHO Executive Board 2010
  • Full report for World Health Assembly 2010
  • Source data available on request for further analysis
conclusions of ims reports to date
Conclusions of IMS reports to date

No firm evidence of a negative impact except in Baltic countries and Malaysia

So far most countries seem to have absorbed the moderate price increases without a loss in medicine consumption

Confident that the data collection methods and the analytic tools available will enable us to detect significant changes as soon as they occur

When such changes are detected, governments have a range of policy instruments to alleviate the situation

More reports will be provided quarterly

http://www.who.int/medicines/areas/policy/imsreport/en/index.html